Hugendubel.info - Die B2B Online-Buchhandlung 

Merkliste
Die Merkliste ist leer.
Bitte warten - die Druckansicht der Seite wird vorbereitet.
Der Druckdialog öffnet sich, sobald die Seite vollständig geladen wurde.
Sollte die Druckvorschau unvollständig sein, bitte schliessen und "Erneut drucken" wählen.
BuchGebunden
447 Seiten
Englisch
Springererschienen am21.12.20214. Aufl.
As more immunotherapeutic agents are used in the clinic, it is important to provide updates about current and ongoing developments in the field to further research efforts and inform treatment decisions.The fourth edition will have a new focus on strategies to overcomethe challenges associated with immunotherapy.mehr
Verfügbare Formate
BuchKartoniert, Paperback
EUR85,59
BuchGebunden
EUR235,39
E-BookPDF1 - PDF WatermarkE-Book
EUR223,63

Produkt

KlappentextAs more immunotherapeutic agents are used in the clinic, it is important to provide updates about current and ongoing developments in the field to further research efforts and inform treatment decisions.The fourth edition will have a new focus on strategies to overcomethe challenges associated with immunotherapy.
Details
ISBN/GTIN978-3-030-79307-4
ProduktartBuch
EinbandartGebunden
Verlag
Erscheinungsjahr2021
Erscheinungsdatum21.12.2021
Auflage4. Aufl.
ReiheAdvances in Experimental Medicine and Biology
Seiten447 Seiten
SpracheEnglisch
IllustrationenVIII, 447 p. 41 illus., 32 illus. in color.
Artikel-Nr.49730256
Rubriken
GenreMedizin

Inhalt/Kritik

Inhaltsverzeichnis
Immune System in Action.- 2. Resistance to Immunotherapy: Mechanisms and Means for Overcoming.- 3. Immunotherapy for Melanoma.- 4. Immunotherapy in Lung Cancer: Are the promises of long-term benefit finally met?.- 5. Landscape of Immunotherapy in Genitourinary Malignancies.- 6. Immuno-oncology for Gynecologic Malignancies.- 7. Immunotherapy for Neuro-oncology.- 8. Immunotherapy in Gastrointestinal Malignancies.- 9. An update on immune based therapies in acute myeloid leukemia: 2021 and beyond!.- 10.  CAR T-cells.- 11.  Skin Reactions to Immune Checkpoint Inhibitors.- 12.  Immunotherapy Mediated luminal Gastrointestinal toxicities.- 13.  Hepatobiliary and Pancreatic Adverse Events .- 14.  Pulmonary toxicities of immunotherapy.- 15.  Immune checkpoint inhibitors (ICIs) related cardiotoxicity.- 16.  Renal Toxicity.- 17.  Immune-Related Oral, Otologic and Ocular Adverse Events.- 18.  Neurologic Toxicities of Immunotherapy.- 19.  Cancer Imaging in Immunotherapy.mehr

Schlagworte

Autor

Dr. Aung Naing is a Professor in the Department of Investigational Cancer Therapeutics at MD Anderson Cancer Center and is also a Principal Investigator on immunotherapy-based clinical trials. Focusing on clinical translation of basic immunobiology, Dr. Naing's research interests are (1) identifying immunologic biomarkers of response to immunotherapy, (2) predicting primary and secondary resistance to immunotherapy, (3) developing immunotherapeutic strategies to overcome resistance, and (4) identifying predictive markers for immune-related adverse events (irAE) associated with immunotherapies.



Dr. Joud Hajjar is an Assistant Professor of Allergy and Immunology and serves as the service chief of adult allergy and immunology at Texas Children's Hospital. She is a member of the Basic and Clinical Immunology Interest group at the American Academy of Allergy Asthma and Immunology, and the Women in Clinical Immunology Committee at the Clinical Immunology Society. Dr. Hajjar's research interests are in inborn errors of immunity, microbiome in the immunocompromised host, and cancer immunotherapy.
Weitere Artikel von
Herausgegeben:Naing, Aung
Weitere Artikel von
Hajjar, Joud